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The benefits of combined treatment with corticosteroids and long-
acting beta agonists
Guidelines for the treatment of COPD recommend that long-acting beta agonists
(LABA) are used initially to maximize lung function and relieve symptoms in patients
with mild to moderate disease who are being treated with short-acting bronchodilators
(www.goldcopd.com). Inhaled corticosteroid (ICS) therapy reduces exacerbation rates
in patients with more severe disease (Burge et al 2000), and so guidelines recommend
that these drugs are used for this purpose primarily in patients with FEV1 <50%
predicted. ICS and LABA can be co-administered using combination inhalers, which
give practical advantages as well as increasing compliance and maximizing the chance
of synergistic interactions between the monocomponents. There is evidence that the
combined LABA/ICS inhalers salmeterol/fluticasone propionate (Sal/FP) (Calverley
et al 2003a) and formoterol/budesonide (F/Bud) (Calverley et al 2003b; Szafranski
et al 2003) reduce exacerbation rates. Our current treatment strategies using LABA
and ICS therefore have different goals (optimizing lung function, symptom relief,
and exacerbation reduction), and are stratified by lung function.
In the current issue, Calverley et al (p 209–18) have re-analyzed data from the
TRISTAN study which compared the effects of Sal/FP, FP alone, Sal alone, and
placebo over 1 year on lung function, exacerbation rates, and health status in order
to evaluate whether the pre-treatment FEV1 influenced these outcome measures. The
FEV1 data were categorized using the arbitary cut off value of 50% predicted, but
also analyzed as a continuous variable. The authors note the limitations of a post hoc
analysis, and that the study was primarily designed to evaluate the difference in
FEV1 between Sal/FP and placebo, rather than differences between the active
treatments. Nevertheless, this paper provides a wealth of important data on the effects
of different treatments on different endpoints across a range of disease severity
stratified by FEV1.
Sal/FP significantly improved the pre-bronchodilator FEV1 at all disease severities
compared with FP, Sal, and placebo. Interestingly, the benefit of Sal/FP compared
with its monocomponents Sal and FP appeared to be synergistic in patients with
more severe disease, but additive in patients with milder disease. It is known that
LABA and ICS have synergistic interactions in vitro (Johnson 2004), and these clinical
trial data suggest that the degree of synergy for lung function depends on disease
severity. FP alone had no significant effect in patients with the most severe disease.
It could be argued that Sal “unlocks” corticosteroid insensitivity in these patients,
leading to a true synergistic effect. Although it is known that Sal/FP reduces airway
inflammation in bronchial biopsies compared with placebo (Barnes et al 2006), no
similar data compare Sal/FP with its monocomponents. Such a study, across a range
of disease severities, would facilitate our understanding of the molecular interactions
between Sal and FP in vivo.
Sal/FP, Sal, and FP all significantly reduced exacerbation rates compared to
placebo, but only in patients with FEV1 <50% predicted. This lung function cut-off
value appears to be useful for predicting which patients are most likely to benefit
from Sal/FP combination therapy to reduce exacerbations. However, the effect of
Sal/FP was similar to that of the monocomponents, raising the question of whether
patients can be treated with moncomponents alone for exacerbation reduction.
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However, there is an advantage of combination therapy over
the monocomponents for lung function and health status.
The optimum treatment strategy for COPD must be to take
a global view of the disease, encompassing a number of
clinical endpoints. With this in mind, the TRISTAN re-
analysis indicates that the advantage of combination therapy
with Sal/FP over the monocomponents is most apparent for
lung function and health status. Indeed, the observed synergistic
effect on lung function between Sal and FP in patients with
more severe disease, and the lack of significant effect of FP on
lung function in these patients, strongly suggests that FP is
most effectively prescribed with Sal in these patients.
The review article by Chung (p 235–42) in the current
issue raises the issue of the dose of Sal/FP used in clinical
practice, as we have most information using a daily FP dose
of 1000ìg, but dose-response effects on different therapeutic
endpoints may exist. Furthermore, while there is no evidence
that the Sal/FP combination is better than its
monocomponents for reducing exacerbations, there are
different data for the F/Bud combination, which is more
effective than its monocomponents (Calverley et al 2003b;
Szafranski et al 2003). The differences between F/Bud study
results and the TRISTAN data may be attributed to different
designs, inclusion criteria, and exacerbation definitions.
However, the ICS and LABA components of Sal/FP and F/
Bud have different pharmacological properties, and are
administered by different inhaler devices, so it is possible
that there may be intrinsic differences in their clinical effect
profiles.
Mannino and Kiri (p 219–33) review in the current issue
strategies for changing the burden of COPD mortality,
including the use of ICS and combination therapies. They
highlight the paucity of data from randomized controlled
trials for a benefit of ICS on survival, except for one meta-
analysis (Sin et al 2005). Non-randomized, observational
cohorts may suffer from immortal time bias, which occurs
when a subject dies before treatment is initiated and so is
included in the control group. In a study free of immortal
time bias, there is a mortality benefit for ICS (Kiri et al
2005), although there are no similar data for combination
therapies. There is clearly a need for more data on survival
with combination therapies from prospective, randomized
trials. The full results of the TORCH (Towards a Revolution in
COPD Health) study, prospectively comparing the effects of
Sal/FP, Sal, FP, and placebo on mortality, exacerbations, lung
function, and health status over 3 years are eagerly awaited.
COPD is a heterogenous disease, and the phenotypes of
disease that may predict disease prognosis or response to
therapy need better definition. The therapeutic response to
corticosteroid therapy is COPD is variable, with the greatest
benefit observed in patients with sputum eosinophilia
(Brightling et al 2000, 2005). Identification of the
characteristics of patients most likely to benefit from
combination therapy with ICS/LABA would allow these
drugs to be used rationally and cost effectively. This will be
a complex task, as combination therapy appears to have
varying effects on different clinical endpoints. It is therefore
possible that the phenotype of patients who respond to
combination therapy may vary with the endpoint studied,
eg, the phenotype of “lung function responders” may
differ from those who show reduced exacerbations. We
need detailed characterization in clinical trials to
understand fully the phenotype of responders and non-
responders.
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